BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36293105)

  • 1. miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs.
    Ravegnini G; Nannini M; Indio V; Serrano C; Gorini F; Astolfi A; Di Vito A; Morroni F; Pantaleo MA; Hrelia P; Angelini S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
    Yoo C; Ryu MH; Jo J; Park I; Ryoo BY; Kang YK
    Cancer Res Treat; 2016 Apr; 48(2):546-52. PubMed ID: 26130666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
    Indio V; Ravegnini G; Astolfi A; Urbini M; Saponara M; De Leo A; Gruppioni E; Tarantino G; Angelini S; Pession A; Pantaleo MA; Nannini M
    Front Immunol; 2020; 11():851. PubMed ID: 32670260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
    Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.
    Fan J; Yang M; Huang B; Wang Z; Luo D; Zhang J; Zhang P; Shi H; Li Y; Nie X
    Diagn Pathol; 2020 Jan; 15(1):8. PubMed ID: 32005261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
    Corless CL; Schroeder A; Griffith D; Town A; McGreevey L; Harrell P; Shiraga S; Bainbridge T; Morich J; Heinrich MC
    J Clin Oncol; 2005 Aug; 23(23):5357-64. PubMed ID: 15928335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
    Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
    [No Abstract]   [Full Text] [Related]  

  • 8. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].
    Qi C; Pan F; Li J; Li Y; Gao J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1280-1284. PubMed ID: 30506540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
    Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
    Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene.
    Indio V; Astolfi A; Tarantino G; Urbini M; Patterson J; Nannini M; Saponara M; Gatto L; Santini D; do Valle IF; Castellani G; Remondini D; Fiorentino M; von Mehren M; Brandi G; Biasco G; Heinrich MC; Pantaleo MA
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
    Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
    Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
    Smrke A; Gennatas S; Huang P; Jones RL
    Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
    He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
    Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
    Cassier PA; Fumagalli E; Rutkowski P; Schöffski P; Van Glabbeke M; Debiec-Rychter M; Emile JF; Duffaud F; Martin-Broto J; Landi B; Adenis A; Bertucci F; Bompas E; Bouché O; Leyvraz S; Judson I; Verweij J; Casali P; Blay JY; Hohenberger P;
    Clin Cancer Res; 2012 Aug; 18(16):4458-64. PubMed ID: 22718859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [c-Kit and PDGFRA mutations and clinico-morphological features of gastrointestinal stromal tumors].
    Beliakov IS; Anurova OA; Snigur PV; Tsyganova IV; Sel'chuk VIu; Mazurenko NN
    Vopr Onkol; 2007; 53(6):677-81. PubMed ID: 18416137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
    JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
    Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
    Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
    Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513
    [No Abstract]   [Full Text] [Related]  

  • 19. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
    Lasota J; Miettinen M
    Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
    Rossi S; Gasparotto D; Miceli R; Toffolatti L; Gallina G; Scaramel E; Marzotto A; Boscato E; Messerini L; Bearzi I; Mazzoleni G; Capella C; Arrigoni G; Sonzogni A; Sidoni A; Mariani L; Amore P; Gronchi A; Casali PG; Maestro R; Dei Tos AP
    Am J Surg Pathol; 2015 Jul; 39(7):922-30. PubMed ID: 25970686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.